$9.09
0.738.73%
Last update: Nov 9, 9:01 AM
Harvard Bioscience Inc
HBIONASDAQ
Harvard Bioscience rose 56.4% from $5.81 to a 1-year high of $9.09, ahead of the S&P 500's +10.5%. Its worst day was May 12 (−20.9%), and its low came Apr 10 at $4.31.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Harvard Bioscience shares rose 13.3%, while the S&P 500 fell 0.0%.
+13.3% · S&P 500 0.0%
Harvard Bioscience shares rose 15.2%, while the S&P 500 rose 0.9%.
+15.2% · S&P 500 +0.9%
Story events cover the past 12 months · Times ET
Harvard Bioscience shares rose 12.4%, while the S&P 500 fell 1.1%.
+12.4% · S&P 500 −1.1%
Harvard Bioscience shares rose 13.4%, while the S&P 500 fell 0.3%.
+13.4%, on 548K shares, the year's heaviest volume · S&P 500 −0.3%
EPS of $0.00 missed the $0.30 estimate on $23.7M revenue (est. $23.1M); FY revenue guidance of $88.3M–$90.0M against the $88.6M consensus.
−2.6% · S&P 500 −1.5%
Harvard Bioscience closed at its lowest level of the year, 25.8% below where the year started.
−19.7% · S&P 500 −0.1%
Harvard Bioscience shares rose 14.0%, while the S&P 500 fell 0.2%.
+14.0% · S&P 500 −0.2%
EPS of $-0.33 missed the $-0.03 estimate on $20.8M revenue (est. $21.2M); Q2 revenue guidance of $20.5M–$22.5M against the $21.9M consensus.
−20.9%, the year's worst day · S&P 500 −0.2%
EPS of $-0.14 beat the $-0.15 estimate on $22.7M revenue (est. $21.4M); FY revenue guidance of $89.1M–$90.9M against the $88.6M consensus.
−4.1% · S&P 500 −0.3%
Where it ended: a 1-year high close of $9.09 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 10, 2026 (EPS est. $-0.27, revenue est. $21.8M).
Nothing in the past 12 months.
All HBIO dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for HBIO and SPY from Benzinga historical bars. Not investment advice.
